Thermo Fisher closes Solventum purification deal

Thermo Fisher Scientific Inc. has completed its acquisition of Solventum Corporation’s purification and filtration business.

Rhea-AI Filing Summary

Thermo Fisher Scientific Inc. has completed its acquisition of Solventum Corporation’s purification and filtration business. The company announced the closing in a press release dated September 2, 2025, following the earliest event date of September 1, 2025.

The acquired operations focus on purification and filtration technologies, which fit within Thermo Fisher’s broader scientific and laboratory solutions portfolio. Details such as purchase price, financing, and expected financial impact are not included in this summary document but are referenced in the attached press release.

Insights

M&A and strategic positioning analyst

Thermo Fisher closes targeted deal for Solventum’s purification and filtration unit.

Thermo Fisher Scientific discloses that it has completed acquiring Solventum Corporation’s purification and filtration business. This adds a specialized set of purification and filtration products and capabilities to Thermo Fisher’s existing scientific tools and services franchise, reinforcing its role as a consolidator in life science tools.

The excerpt does not quantify the size of the acquired business, the purchase consideration, or expected synergies, so the financial impact cannot be assessed from this text alone. However, the transaction is presented as fully closed as of early September 2025, not merely agreed.

Further detail on integration plans, revenue contribution, and cost structure is referenced as being in a 99.1 press release dated September 2, 2025. Subsequent periodic reports may outline how this purification and filtration business affects segment performance and margins once it is folded into Thermo Fisher’s operating results.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Thermo Fisher Scientific (TMO) disclose in this 8-K?

Thermo Fisher Scientific disclosed that it completed the acquisition of Solventum Corporation’s purification and filtration business. The company reported that closing of this deal was announced in a press release dated September 2, 2025, attached as Exhibit 99.1 for additional detail.

When did Thermo Fisher complete the Solventum purification and filtration acquisition?

Thermo Fisher links the transaction to an earliest event date of September 1, 2025, and issued a press release on September 2, 2025 announcing completion. The 8-K confirms the deal is closed rather than pending, referencing that press release as Exhibit 99.1.

What business did Solventum sell to Thermo Fisher Scientific (TMO)?

Solventum Corporation sold its purification and filtration business to Thermo Fisher Scientific. The description in the disclosure indicates this unit focuses on purification and filtration technologies, which align with Thermo Fisher’s scientific and laboratory solutions offerings across research, diagnostics, and manufacturing workflows.

Where can investors find more details on Thermo Fisher’s Solventum deal?

More details are provided in Thermo Fisher’s press release attached as Exhibit 99.1, dated September 2, 2025. The 8-K states this press release is incorporated by reference, meaning it forms part of the official disclosure about the completed acquisition.

Does the Thermo Fisher 8-K state that the Solventum transaction is fully closed?

Yes. Thermo Fisher states that it issued a press release announcing the completion of its acquisition of Solventum Corporation’s purification and filtration business. The language describes the acquisition as completed, not conditional or pending, as of early September 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/02/2025 - 08:03 AM Learn about SEC filing dates

0000097745FALSE00000977452025-09-012025-09-010000097745us-gaap:CommonStockMember2025-09-012025-09-010000097745tmo:SeniorNotes3200Due2026Member2025-09-012025-09-010000097745tmo:SeniorNotes1.40Due2026Member2025-09-012025-09-010000097745tmo:A1.45SeniorNotesDue2027Member2025-09-012025-09-010000097745tmo:SeniorNotes175Due2027Member2025-09-012025-09-010000097745tmo:SeniorNotes0.500Due2028Member2025-09-012025-09-010000097745tmo:SeniorNotes1.375Due2028Member2025-09-012025-09-010000097745tmo:SeniorNotes1.95Due2029Member2025-09-012025-09-010000097745tmo:SeniorNotes0.875Due2031Member2025-09-012025-09-010000097745tmo:SeniorNotes2375Due2032Member2025-09-012025-09-010000097745tmo:SeniorNotes3650Due2034Member2025-09-012025-09-010000097745tmo:SeniorNotes2.875Due2037Member2025-09-012025-09-010000097745tmo:SeniorNotes1.500Due2039Member2025-09-012025-09-010000097745tmo:SeniorNotes1.875Due2049Member2025-09-012025-09-01

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 1, 2025

THERMO FISHER SCIENTIFIC INC.

(Exact name of Registrant as specified in its Charter)

Delaware

1-8002

04-2209186

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

168 Third Avenue

Waltham, Massachusetts 02451

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 622-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $1.00 par value

TMO

New York Stock Exchange

3.200% Notes due 2026

TMO 26B

New York Stock Exchange

1.400% Notes due 2026

TMO 26A

New York Stock Exchange

1.450% Notes due 2027

TMO 27

New York Stock Exchange

1.750% Notes due 2027

TMO 27B

New York Stock Exchange

0.500% Notes due 2028

TMO 28A

New York Stock Exchange

1.375% Notes due 2028

TMO 28

New York Stock Exchange

1.950% Notes due 2029

TMO 29

New York Stock Exchange

0.875% Notes due 2031

TMO 31

New York Stock Exchange

2.375% Notes due 2032

TMO 32

New York Stock Exchange

3.650% Notes due 2034

TMO 34

New York Stock Exchange

2.875% Notes due 2037

TMO 37

New York Stock Exchange

1.500% Notes due 2039

TMO 39

New York Stock Exchange

1.875% Notes due 2049

TMO 49

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 8.01    Other Events.

On September 2, 2025, Thermo Fisher Scientific Inc. (“Thermo Fisher”) issued a press release announcing the completion of its acquisition of Solventum Corporation’s purification and filtration business. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

99.1    Press Release of Thermo Fisher Scientific Inc., dated September 2, 2025.

104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						THERMO FISHER SCIENTIFIC INC.
Date:			September 2, 2025			By:			/s/ Thomas B. Shropshire
									Thomas B. Shropshire
									Senior Vice President and General Counsel

3